Electromagnetic polarizabilities of the spin- 1 2 singly heavy baryons in heavy baryon chiral perturbation theory
Physical Review D · 17.03.2025 · 111 (5)
DOI: 10.1103/physrevd.111.054019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physical Review D, online erschienen am 17.03.2025. Verfasst von Yan-Ke Chen und 3 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, European Research Council.
Abstract (Originalsprache)
We calculate the electromagnetic polarizabilities of the spin- 1 2 singly heavy baryons in the heavy baryon chiral perturbation theory up to O ( p 3 ) . We estimate the low-energy constants using the magnetic moments of singly charmed baryons from lattice QCD simulations and the experimental decay widths of Σ c and Σ c * . Our results indicate that the long-range chiral corrections make significant contributions to the polarizabilities. Additionally, the magnetic dipole transitions B 6 * → B 6 + γ also provide large contribution to the magnetic polarizabilities.
Förderung
- National Natural Science Foundation of China
- European Research Council
Zitieren
APA
Chen, Y., Wen, L., Meng, L., & Zhu, S. (2025). Electromagnetic polarizabilities of the spin- 1 2 singly heavy baryons in heavy baryon chiral perturbation theory. Physical Review D, 111(5). https://doi.org/10.1103/physrevd.111.054019
Vancouver
Chen Y, Wen L, Meng L, Zhu S. Electromagnetic polarizabilities of the spin- 1 2 singly heavy baryons in heavy baryon chiral perturbation theory. Physical Review D. 2025;111(5). doi:10.1103/physrevd.111.054019
BibTeX
@article{Chen2025,
author = {Chen, Yan-Ke and Wen, Liang-Zhen and Meng, Lu and Zhu, Shi-Lin},
title = {Electromagnetic polarizabilities of the spin- 1 2 singly heavy baryons in heavy baryon chiral perturbation theory},
journal = {Physical Review D},
year = {2025},
volume = {111},
number = {5},
doi = {10.1103/physrevd.111.054019}
}
EUVIMED